News

Examining the Future: Lineage Cell Therapeutics's Earnings Outlook
Analysts anticipate Lineage Cell Therapeutics to report an earnings per share (EPS) of $-0.03. Anticipation surrounds Lineage ...
The Manila Times3h
Axovia Therapeutics Presents New Preclinical Data for AXV-101 for the Treatment of Blindness Associated with BBS Mutations at ASGCT
"A new dosing regimen to treat Bardet-Biedl Syndrome 1 (BBS1) retinal degeneration with AXV-101 (AAV9-BBS1) improves ...